跨性别者合并人类免疫缺陷病毒感染者的药物治疗考虑因素。
Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus.
机构信息
College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
School of Pharmacy, The University of Kansas, Kansas City, Kansas, USA.
出版信息
Pharmacotherapy. 2021 Mar;41(3):299-314. doi: 10.1002/phar.2499. Epub 2021 Feb 27.
Abstract
Pharmacotherapy considerations are often a concern for transgender individuals who are living with human immunodeficiency virus (HIV) due to concerns for drug-drug interactions between their hormone and antiretroviral therapies. Many of the first-line therapies offered to patients for the management of HIV have reduced concerns for safety, resistance, and drug-drug interactions. In this review, we highlight common medications and important considerations for caring for transgender people living with HIV.
摘要
药物治疗的考虑因素通常是感染人类免疫缺陷病毒（HIV）的跨性别者关注的问题，因为他们的激素治疗和抗逆转录病毒治疗之间存在药物相互作用的担忧。许多为管理 HIV 而提供给患者的一线治疗方法减少了对安全性、耐药性和药物相互作用的担忧。在这篇综述中，我们强调了为感染 HIV 的跨性别者提供护理时常见的药物和重要的考虑因素。
相似文献
1
Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus.跨性别者合并人类免疫缺陷病毒感染者的药物治疗考虑因素。
Pharmacotherapy. 2021 Mar;41(3):299-314. doi: 10.1002/phar.2499. Epub 2021 Feb 27.
2
HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals.HIV 抗病毒治疗和 HIV 暴露前预防在跨性别者中的应用。
Drugs. 2020 Jul;80(10):965-972. doi: 10.1007/s40265-020-01313-z.
3
Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns.HIV 感染者中的跨性别女性由于药物相互作用的顾虑，经常以不同于规定的方式服用抗逆转录病毒疗法和/或雌性激素疗法。
LGBT Health. 2017 Oct;4(5):371-375. doi: 10.1089/lgbt.2017.0057. Epub 2017 Sep 6.
4
Human Immunodeficiency Virus in Transgender Persons. transgender 跨性别者
Endocrinol Metab Clin North Am. 2019 Jun;48(2):453-464. doi: 10.1016/j.ecl.2019.02.007. Epub 2019 Mar 23.
5
Drug-drug Interactions Among Thai Transgender Women Living with Human Immunodeficiency Undergoing Feminizing Hormone Therapy and Antiretroviral Therapy: The iFACT Study.接受激素疗法和抗逆转录病毒疗法的泰国跨性别女性艾滋病毒感染者的药物-药物相互作用：iFACT 研究。
Clin Infect Dis. 2021 Feb 1;72(3):396-402. doi: 10.1093/cid/ciaa038.
6
Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus.跨性别女性艾滋病毒感染者获得并维持治疗的障碍和促进因素。
Ann Behav Med. 2014 Feb;47(1):5-16. doi: 10.1007/s12160-013-9565-8.
7
Safety and Efficacy of Weight-Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug-Drug Interactions with Antiretroviral Therapy.肥胖症患者接受减肥药物治疗的安全性和疗效：文献综述及与抗逆转录病毒治疗的潜在药物相互作用。
Pharmacotherapy. 2019 Dec;39(12):1204-1215. doi: 10.1002/phar.2342. Epub 2019 Nov 3.
8
Preexposure Prophylaxis for Human Immunodeficiency Virus Infection for Men Who Have Sex with Men and Transgender Persons:: What Dermatologists Need to Know.男男性行为者和跨性别者的人免疫缺陷病毒感染的暴露前预防：皮肤科医生需要了解什么。
Dermatol Clin. 2020 Apr;38(2):233-238. doi: 10.1016/j.det.2019.10.008. Epub 2019 Nov 23.
9
Sexually Transmitted Infection Testing Among Transgender Women Living with Human Immunodeficiency Virus in the United States: Medical Monitoring Project, 2015-2019.美国感染人类免疫缺陷病毒的跨性别女性中的性传播感染检测：医学监测项目，2015-2019 年。
Clin Infect Dis. 2021 Sep 7;73(5):899-902. doi: 10.1093/cid/ciab134.
10
Navigating Human Immunodeficiency Virus and Primary Care Concerns Specific to the Transgender and Gender-Nonbinary Population.应对人类免疫缺陷病毒以及针对跨性别和性别非二元人群的初级保健问题
Open Forum Infect Dis. 2022 Mar 23;9(4):ofac091. doi: 10.1093/ofid/ofac091. eCollection 2022 Apr.
引用本文的文献
1
Drug-Drug Interactions in Transgender Patients Receiving Antiretroviral and Hormonal Therapy: A Systematic Review of Clinical Studies and Reports.接受抗逆转录病毒和激素治疗的跨性别患者中的药物相互作用：临床研究与报告的系统评价
Cureus. 2025 Apr 8;17(4):e81918. doi: 10.7759/cureus.81918. eCollection 2025 Apr.
2
An update on drug-drug interactions in older adults living with human immunodeficiency virus (HIV).老年人类免疫缺陷病毒（HIV）感染者药物-药物相互作用的最新研究进展。
Expert Rev Clin Pharmacol. 2024 Jul;17(7):589-614. doi: 10.1080/17512433.2024.2350968. Epub 2024 Jun 30.
3
Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy-Update 2022: Systematic Review.接受抗逆转录病毒治疗的人类免疫缺陷病毒感染者中药物相互作用的临床相关性——2022年更新：系统评价
Pharmaceutics. 2023 Oct 18;15(10):2488. doi: 10.3390/pharmaceutics15102488.
4
Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.《跨性别和性别多样化人群健康照护标准》第8版
Int J Transgend Health. 2022 Sep 6;23(Suppl 1):S1-S259. doi: 10.1080/26895269.2022.2100644. eCollection 2022.
5
Navigating Human Immunodeficiency Virus and Primary Care Concerns Specific to the Transgender and Gender-Nonbinary Population.应对人类免疫缺陷病毒以及针对跨性别和性别非二元人群的初级保健问题
Open Forum Infect Dis. 2022 Mar 23;9(4):ofac091. doi: 10.1093/ofid/ofac091. eCollection 2022 Apr.
6
Southern African HIV Clinicians' Society gender-affirming healthcare guideline for South Africa.南部非洲艾滋病毒临床医生协会针对南非的性别肯定性医疗保健指南。
South Afr J HIV Med. 2021 Sep 28;22(1):1299. doi: 10.4102/sajhivmed.v22i1.1299. eCollection 2021.
本文引用的文献
1
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.恩曲他滨和丙酚替诺福韦艾拉酚胺与恩曲他滨和富马酸替诺福韦二吡呋酯用于 HIV 暴露前预防（DISCOVER）：一项随机、双盲、多中心、阳性对照、3 期、非劣效性临床试验的主要结果。
Lancet. 2020 Jul 25;396(10246):239-254. doi: 10.1016/S0140-6736(20)31065-5.
2
Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.接受女性化激素治疗的跨性别女性中富马酸替诺福韦二吡呋酯和恩曲他滨的血浆和细胞内药代动力学。
J Antimicrob Chemother. 2020 May 1;75(5):1242-1249. doi: 10.1093/jac/dkaa016.
3
Drug-drug Interactions Among Thai Transgender Women Living with Human Immunodeficiency Undergoing Feminizing Hormone Therapy and Antiretroviral Therapy: The iFACT Study.接受激素疗法和抗逆转录病毒疗法的泰国跨性别女性艾滋病毒感染者的药物-药物相互作用：iFACT 研究。
Clin Infect Dis. 2021 Feb 1;72(3):396-402. doi: 10.1093/cid/ciaa038.
4
Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.与顺性别男性相比，同时服用雌激素的跨性别女性服用口服 HIV 暴露前预防药物时，替诺福韦和恩曲他滨的浓度明显较低。
J Int AIDS Soc. 2019 Nov;22(11):e25405. doi: 10.1002/jia2.25405.
5
Adherence to Antiretroviral Therapy Among Transgender and Gender Nonconforming People Living with HIV: Findings from the 2015 U.S. Trans Survey.感染艾滋病毒的跨性别者和性别不一致者的抗逆转录病毒治疗依从性：2015年美国跨性别者调查结果
Transgend Health. 2019 Oct 25;4(1):262-269. doi: 10.1089/trgh.2019.0050. eCollection 2019.
6
The Effect of Efavirenz on Estradiol Metabolism in Transgender Women.依法韦仑对跨性别女性雌二醇代谢的影响。
Transgend Health. 2019 Sep 4;4(1):197-199. doi: 10.1089/trgh.2019.0018. eCollection 2019.
7
Changes in HIV Preexposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men - 20 Urban Areas, 2014 and 2017.男男性行为者中 HIV 暴露前预防意识和使用情况的变化 - 2014 年和 2017 年 20 个城市地区。
MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603. doi: 10.15585/mmwr.mm6827a1.
8
Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study.激素治疗与暴露前预防药物相互作用在跨性别女性中的研究：iFACT 研究。
J Int AIDS Soc. 2019 Jul;22(7):e25338. doi: 10.1002/jia2.25338.
9
Required Sexual Orientation and Gender Identity Reporting by US Health Centers: First-Year Data.美国健康中心要求报告性取向和性别认同：第一年数据。
Am J Public Health. 2019 Aug;109(8):1111-1118. doi: 10.2105/AJPH.2019.305130. Epub 2019 Jun 20.
10
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.HIV 感染预防的暴露前预防：美国预防服务工作组推荐声明。
JAMA. 2019 Jun 11;321(22):2203-2213. doi: 10.1001/jama.2019.6390.
Zotero 插件